All Pharma News
AlloVir lays off 95% of staffers after shuttering PhIII cell therapy trials 

AlloVir lays off 95% of staffers after shuttering PhIII cell therapy trials 
Anna Brown ENDPTS
05 Jan 2024
Share Share
Reeling from triple phase 3 failure, AlloVir cuts 95% of staff

Reeling from triple phase 3 failure, AlloVir cuts 95% of staff
Annalee Armstrong FIERCE BIOTECH
05 Jan 2024
Share Share
AlloVir to wind down PhIII trials for futility

AlloVir to wind down PhIII trials for futility
Amber Tong ENDPTS
26 Dec 2023
Share Share
Triple phase 3 disaster sends AlloVir shares plunging 64%

Triple phase 3 disaster sends AlloVir shares plunging 64%
James Waldron FIERCE BIOTECH
21 Dec 2023
Share Share
AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
BUSINESSWIRE
16 Nov 2023
Share Share
AlloVir Reports Third Quarter 2023 Financial Results

AlloVir Reports Third Quarter 2023 Financial Results
BUSINESSWIRE
02 Nov 2023
Share Share
AlloVir to Present at Upcoming Investor Conferences

AlloVir to Present at Upcoming Investor Conferences
BUSINESSWIRE
28 Aug 2023
Share Share
AlloVir Reports Second Quarter 2023 Financial Results

AlloVir Reports Second Quarter 2023 Financial Results
BUSINESSWIRE
03 Aug 2023
Share Share
AlloVir Announces Proposed Public Offering of Common Stock

AlloVir Announces Proposed Public Offering of Common Stock
BUSINESSWIRE
21 Jun 2023
Share Share
AlloVir Announces Pricing of Public Offering of Common Stock

AlloVir Announces Pricing of Public Offering of Common Stock
BUSINESSWIRE
21 Jun 2023
Share Share